Evaluating the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) We expect to enroll 6 patients in this part of the project.
|Effective start/end date||9/18/15 → 8/31/19|
- University of Texas Southwestern Medical School (GMO-170910 // 5U01DK058369-19)
- National Institute of Diabetes and Digestive and Kidney Diseases (GMO-170910 // 5U01DK058369-19)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.